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gd T cells rapidly secrete inflammatory cytokines at
barrier sites that aid in protection from pathogens,
but mechanisms limiting inflammatory damage
remainunclear.We found that retinoid-relatedorphan
receptor gamma-t (RORgt) and interleukin-7 (IL-7)
influence gd T cell homeostasis and function by regu-
lating expression of the inhibitory receptor, B and T
lymphocyte attenuator (BTLA). The transcription fac-
tor RORgt, via its activating function-2 domain,
repressed Btla transcription, whereas IL-7 increased
BTLA levels on the cell surface. BTLA expression
limited gd T cell numbers and sustained normal gd
T cell subset frequencies by restricting IL-7 respon-
siveness and expansion of the CD27RORgt+ pop-
ulation. BTLA also negatively regulated IL-17 and
TNF production in CD27 gd T cells. Consequently,
BTLA-deficient mice exhibit enhanced disease in a
gd T cell-dependent model of dermatitis, whereas
BTLA agonism reduced inflammation. Therefore, by
coordinating expression of BTLA, RORgt and IL-7
balancesuppressiveandactivationstimuli to regulate
gd T cell homeostasis and inflammatory responses.
INTRODUCTION
Secondary lymphoid organs such as the spleen, lymph nodes,
and Peyer’s patches (PP) promote cellular interactions for effi-
cient adaptive immune responses (Ruddle and Akirav, 2009).
Emerging evidence indicates that secondary lymphoid organs
also provide a critical location for cells mediating early innate de-
fenses (Bekiaris et al., 2008; Junt et al., 2007; Kastenmu¨ller et al.,
2012; Schneider et al., 2008). Specialized subsets of innate-like
T cells, B cells, and innate lymphoid cells (ILCs) reside within the
elaborate architecture of lymphoid organs formed by highly
differentiated stromal cells and myeloid cells (Junt et al., 2008).
A balance of activating and inhibitory signals controls homeosta-
sis of cells within secondary lymphoid organs, but the nature of
these cellular circuits andmolecular pathways, particularly those
involving inhibitory pathways, are incompletely defined. Such
knowledge could reveal new opportunities for intervention in
pathological immune responses (Germain, 2012).1082 Immunity 39, 1082–1094, December 12, 2013 ª2013 Elsevier InThe differentiation of specific subsets of T cells is promoted by
expression of the transcription factor retinoid-related orphan re-
ceptor-g isoform-t (RORgt) (encoded by Rorc) (Jetten, 2009).
RORgt is a member of the ROR family of transcription factors
that transactivate gene expression by recruiting nuclear repres-
sors or activators containing an LXXLL motif via their activating
function-2 (AF2) domain to canonical ROR DNA binding sites
through their DNA binding domain (DBD) (Jetten, 2009). In
T cells, RORgt binds and activates the Il17 promoter (Zhang
et al., 2008), inducing expression of the proinflammatory cyto-
kine IL-17, driving the differentiation of conventional CD4+ T
helper (Th17) cells, and sustaining innate-like gamma-delta (gd)
T cells (Ivanov et al., 2006; Martin et al., 2009; Sutton et al.,
2009). Phenotypic profiling of gd T cells identified two broad sub-
groups based on the expression of CD27, amember of the tumor
necrosis factor receptor superfamily (TNFRSF) (Ribot et al.,
2009). The CD27+ subset produces IFN-g, whereas the CD27
subset produces IL-17 (Ribot et al., 2009). During development,
gd T cells are largely dependent on IL-7 signaling (He andMalek,
1996; Maki et al., 1996), which regulates the survival of early
thymic progenitors (Malissen et al., 1997) and induces V(D)J
recombination in the TCR-g locus (Schlissel et al., 2000). More-
over, IL-7 maintains the homeostasis of gd T cells (Baccala et al.,
2005) and preferentially expands the CD27IL-17+ subset
(Michel et al., 2012). The capacity of gd T cells to produce IL-
17 is acquired during thymic differentiation, independently of
TCR signaling (Haas et al., 2012), a feature pointing to their
bona fide innate nature. gd T cells have emerged as potent
inflammatory effectors that can be activated through innate as
well as antigen receptors, either of which initiate rapid responses
to infection (Vantourout and Hayday, 2013; Willcox et al., 2012).
RORgt is also essential for the differentiation of group 3 ILCs,
such as lymphoid tissue inducer (LTi) cells, which are required in
the embryo for the development of secondary lymphoid organs
(Cupedo et al., 2009; Eberl et al., 2004; Mebius et al., 1997), or
adult IL-22-secreting ILCs (CD134+IL-22+ ILCs) (Kim et al.,
2003; Luci et al., 2009; Sanos et al., 2009; Satoh-Takayama
et al., 2008), which are important for protection against intestinal
infections (Sonnenberg et al., 2012; Tumanov et al., 2011) and
induce signals for survival of activated lymphocytes (Bekiaris
et al., 2009; Withers et al., 2012). The conservation of the ILC
lineage in mice and primates (Sonnenberg et al., 2012) under-
scores the importance of these cells in the rapid innate defense
mechanisms in lymphoid tissues.
The broad expression profile in hematopoietic cells of the
inhibitory receptor, B and T lymphocyte attenuator (BTLA) (Hanc.
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Figure 1. Reduced BTLA Expression in
CD27– gd T Cells
Lymphocytes isolated from the iLN of Rorcgfp/+
mice were analyzed by flow cytometry for BTLA
expression and the indicated T cell subset surface
markers. Expression of RORgt and TCRb (A),
BTLA and TCRb in RORgt-gated cells (B), TCRgd
and TCRb in RORgt-gated cells (C), BTLA and
RORgt in gd T cells (E), CD27 and RORgt in gd
T cells (G), and BTLA and CD27 in RORgt (left)
and RORgt+ (right) gd T cells (H). Mean fluorescent
intensity (MFI) for BTLA expression in TCRgd+ and
TCRb+ cells (D), in RORgt and RORgt+ gd T cells
(F), and in CD27+RORgt, CD27+RORgt+, and
CD27RORgt+ gd T cells (I). Each FACS plot is
representative of six mice; in graphs, each symbol
represents a mouse and lines are medians. See
also Figure S1.
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BTLA Inhibits Inflammatory gd T Cellset al., 2004; Hurchla et al., 2005), suggested a potential role in
regulation of innate-like T cells and ILCs. BTLA belongs to the
immunoglobulin superfamily, contains two immunoreceptor
tyrosine-based inhibitory motifs (ITIMs), and associates with
the Src-homology domain 2 (SH2)-containing protein tyrosine
phosphatase-1 (SHP-1) and SHP-2 (Watanabe et al., 2003).
Through ligation with the herpesvirus entry mediator (HVEM,
TNFRSF14) (Cheung et al., 2009; Sedy et al., 2005), BTLA main-
tains the homeostasis of dendritic cells (De Trez et al., 2008) and
memory T cells (Krieg et al., 2007) and plays an important role in
limiting T cell activation (Sedy et al., 2005; Watanabe et al.,
2003). In contrast to other inhibitory receptors that are induced
after activation (Odorizzi and Wherry, 2012), BTLA is constitu-
tively expressed in most immune cells (Murphy and Murphy,
2010). However, BTLA expression varies substantially among
different lymphoid and myeloid cell types (Hurchla et al., 2005),Immunity 39, 1082–1094, Desuggesting that regulation of BTLA
expression may be an important factor
in controlling homeostasis in lymphoid
tissues.
In this study we show that RORgt tran-
scriptionally represses Btla, accounting
for its low expression in CD27RORgt+
gd T cells and ILCs. In contrast, IL-7 in-
duces BTLA expression in the majority
of gd T cells and ILCs, serving to counter
regulate RORgt. Our data further demon-
strate that BTLA limits gd T cell numbers
in the thymus and is a negative regulator
of gd T cell subset homeostasis in lymph
nodes. The defect in homeostasis in the
absence of BTLA can be explained by
the hyperresponsiveness of BTLA-defi-
cient CD27 gd T cells to IL-7. BTLA
regulates the production of IL-17 and
TNF in a gd T cell-subset-specific
manner. Furthermore, BTLA-deficient an-
imals are susceptible to gd T cell-depen-
dent dermatitis, whereas BTLA agonism
limited disease. This result shows thatRORgt and IL-7 form a regulatory circuit that impinges on
BTLA to control the homeostasis and inflammatory responses
of innate-like T cells.
RESULTS
RORgt+ Lymphocytes Express Reduced Levels of BTLA
In order to define the expression of BTLA in innate lymphocyte
populations, we used Rorc reporter mice expressing GFP
(Rorcgfp/+ mice) (Eberl et al., 2004) to discriminate cellular sub-
sets. Within the RORgt+ population of inguinal lymph nodes
(iLNs), we distinguished BTLA+TCRb+ and BTLAloTCRb cells
(Figures 1Aand1B). AmongRORgt+ cells, theBTLAloTCRbpop-
ulation comprised>95%ofgdT cells (Figure 1C) and in general all
gd T cells (RORgt+ and RORgt alike) expressed lower (4-fold)
amounts of BTLA than did conventional T cells (Figure 1D).cember 12, 2013 ª2013 Elsevier Inc. 1083
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Figure 2. RORgt Is a Transcriptional Repressor of Btla
(A) Expression of RORgt and CD127 in freshly isolated lymphocytes gated on TCRb live cells from the iLN (left) and PP (right) of Rorcgfp/+ mice (representative of
eight mice).
(B and C) MFI for RORgt-GFP expression in iLN gd T cells and PP ILCs (B) and for BTLA expression in RORgt+ gdT cells and ILCs (C). Each symbol represents a
mouse and in (B) lines are medians.
(D) Expression of BTLA and GFP in cells transduced with pMSCV-IRES-GFP-RORgt retrovirus (RV-RORgt) or with empty retrovirus (RV) (representative of two
transduction experiments and six different passages after transduction).
(E)mRNA levels (relative to L32) ofRorc andBtla in FACS-sorted RORgt-GFP, RORgt-GFPlo, and RORgt-GFPhi cells that were transducedwith RV-RORgt (each
symbol represents a different passage of the indicated FACS-sorted cell populations).
(F) VISTA plot of sequence similarity (>70%, 100 bp, pink) between the 5 kb promoter regions of the human and mouse BTLA-coding genes and graphical
representation of the conserved RORgt binding sites and their positions relative to the transcription start (indicated by arrow).
(G) PCR analysis via primers specific for the RORgt binding sites 49 and 369 after a ChIP assay with anti-RORg or control IgG in RV-RORgt-transduced cells
(representative of two experiments).
(legend continued on next page)
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BTLA Inhibits Inflammatory gd T CellsHowever, there was a difference in surface BTLA between the
RORgt+ and RORgt gd T cells (1.3-fold) (Figures 1E and 1F).
We identified lower amounts of BTLA in RORgt+ gd T cells
lacking CD27 compared with CD27+ cells, indicating an addi-
tional way in which to regulate BTLA expression (Figures
1G–1I). Among lymph node RORgt+ cells, the CD27 gd T cell
subset, which is associated with IL-17 production and autoim-
munepathology, expressed the lowest amounts of BTLA (Figures
1G–1I).
We observed both BTLAloTCRb and BTLA+TCRb+ RORgt+
populations in intestinal Peyer’s patches (PP) (Figures S1A and
S1B available online). In contrast to iLN, more than 90% of the
BTLAloTCRb lymphocytes were ILCs, defined by the lack of
TCRgd expression (Figure S1C). BTLA expression by ILCs was
also reduced compared with conventional TCRb+ T cells (Fig-
ure S1D) and was 2-fold reduced compared to iLN RORgt+
gdT cells (Figure S1E). Furthermore, we observed the lowest sur-
face BTLA expressed in RORgt+ ILCs compared with RORgt
Thy1.2+CD127+ cells (Figure S1F). In contrast, HVEM levels
were nearly the same between TCRb and TCRb+ cells in all
lymphoid organs (Figures S1N and S1O).
In addition, we found that human innate lymphoid cells in
blood (CD3CD117+) expressed substantially lower BTLA levels
than did conventional T cells (CD3+CD117 cells) (Figure S1G),
whereas IL-22-producing CD117+ ILCs from human tonsils had
undetectable surface BTLA (Figures S1H and S1I). We found
similar downregulation of BTLA in RORgt+ differentiated Th17
cells compared to unpolarized cells and in double-positive
thymocytes compared to single positive (Figures S1J–S1M) as
previously reported (Han et al., 2004; Hurchla et al., 2005).
Thus, overall there was a trend of less BTLA expression in
RORgt+ cells in all lymphoid compartments examined in human
and mouse, indicating a conserved counter-regulatory relation-
ship between these two factors.
RORgt Is a Transcriptional Repressor of Btla
The selective downmodulation of BTLA within RORgt+ innate
lymphocytes in mouse and human suggested a potential regula-
tory interaction. We observed the greatest expression of RORgt
in PP-derived ILCs, 5.5-fold more than in gd T cells from the iLN
(Figures 2A and 2B). Together with the reduced amount of BTLA
in ILCs (Figures 2C and S1E), these data suggest an inverse cor-
relation between RORgt and BTLA expression. To test whether
RORgt antagonized BTLA expression, we ectopically expressed
RORgt by using an IRES-GFP retrovirus (Ivanov et al., 2006) in
a BTLA+ mouse T cell line (Cheung et al., 2009). We found that
ectopic expression of high amounts of RORgt resulted in
decreased BTLA expression (Figures 2D and 2E). Furthermore,
knockdown of RORgt in these cells restored BTLA expression
(Figure S2A) whereas treatment of RORgt-expressing Jurkat
cells with the RORgt inhibitor digoxin induced expression of
BTLA mRNA and protein (Figure S2B), indicating active
RORgt-dependent suppression of BTLA.(H) Btla promoter reporter activity in Jurkat cells cotransfected with wild-type or
(mean ± SEM of two experiments with two replicates each).
(I) Btla promoter reporter activity in Jurkat cells cotransfected with wild-type prom
2 (AF2) mutant or DNA binding domain (DBD) mutant RORgt (mean ± SEM of tw
See also Figure S2.
ImmIn order to determine whether RORgt directly repressed BTLA
transcription, we analyzed the Btla and BTLA promoters for
conserved regulatory regions. We found two conserved canoni-
cal RORgt binding sites (Jetten, 2009) located at232 and +124
in the human and at369 and49 in themouse genes encoding
BTLA (Figures 2F and S2E). We next used chromatin immuno-
precipitation (ChIP) and PCR amplification to determine whether
ectopically expressedRORgt bound to theBtla locus (Figure 2D).
Both conserved sites in the mouse promoter were precipitated
with anti-RORgt Ab (Figure 2G), although the 49 site amplified
a stronger signal in transfected cells and in primary mouse thy-
mocytes in which we probed for endogenous RORgt (Fig-
ure S2C). We next cloned the proximal 0.5 kb Btla promoter
into a luciferase reporter to determine how RORgt regulates pro-
moter activity. In this regard, titrating quantities of RORgt sup-
pressed activity of the wild-type promoter but not a promoter
with mutations at positions 369 and 49 (Figure 2H), directly
demonstrating that RORgt can function as a transcriptional
repressor for BTLA (Figure 2H). Although the 369 site contrib-
utes more to BTLA suppression, mutation of both sites is
required for optimal BTLA promoter activity (Figure S2D). We
further sought to determine how RORgt mediates repressive
activity by truncating either its DBD or its AF2 domain, which
may recruit transcriptional repressors (Figures S2F–S2H). Btla
promoter activity was partially restored when the RORgt AF2
region was truncated and enhanced when the DBD regions
were truncated (Figure 2I). Thus, regulation of Btla requires
RORgt binding to the promoter as well as interactions with a
transcriptional corepressor.
BTLA Negatively Regulates Homeostasis of gd T Cells in
Lymph Nodes
We next sought to determine whether the regulation of BTLA by
RORgt resulted in altered distribution of gd T cell subsets in the
iLN. Among gd T cells we observed an increase in the frequency
and numbers of CD27 cells in BTLA-deficient iLN compared to
wild-type (Figures 3A, 3B, and 3D–3H), with a more pronounced
skewing toward Vg2-expressing cells, possibly reflecting unre-
stricted embryonic development of these cells in the absence
of BTLA (Figure 3C; Haas et al., 2012). CD27+ gd T cells trended
toward lower numbers in iLN and total gd T cell numbers were
not different between wild-type and Btla/ mice (Figures
3D–3H). Together these data indicate that BTLA acts via a cell-
intrinsic mechanism to repress expansion of CD27 cells within
the gd T cell niche. In the absence of BTLA, the increase in
CD27 cell numbers resulted in a redistribution of the major gd
T cell subsets (Figure 3I).
In order to determinewhether expansion of CD27 gd T cells in
the periphery of BTLA-deficient animals originated during devel-
opment, we assessed the expression of BTLA in thymic gd T cell
subsets. In this regard, the CD27 subset showed lower BTLA
expression than did the CD27+ subset, similar to that in lymph
nodes (Figures S3A–S3C). Thymic TCRgd+ cell numbers weremutated promoter and the indicated amounts of RORgt-expressing plasmid
oter in the presence or absence of wild-type (WT) or activation function domain
o experiments with two replicates each).
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Figure 3. BTLA Negatively Regulates the Homeostasis of gd T Cells in Lymph Nodes
Lymphocytes isolated from the iLN of Btla+/+ and Btla/ mice were analyzed for TCRgd, TCRb, CD27, and Vg2 expression by flow cytometry.
(A) Expression of CD27 and Vg2 in TCRgd+TCRb gated cells from Btla+/+ and Btla/ mice.
(B) Ratio of CD27:CD27+ gd T cells in Btla+/+ and Btla/ mice.
(C) Offset overlayed histograms indicate the increase in CD27Vg2+ cells in Btla/ mice.
(D–H) Numbers of gd T cells: (D) total, (E) CD27, (F) CD27+, (G) CD27Vg2, (H) CD27Vg2+.
(I) Pie charts showing the distribution of CD27+, CD27Vg2+, and CD27Vg2 gd T cells in Btla+/+ (top) and Btla/ (bottom) mice (*p < 0.05). Each FACS plot is
representative of nine mice from three experiments; in the graphs, each symbol represents a mouse and lines are medians.
(legend continued on next page)
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BTLA Inhibits Inflammatory gd T Cellsincreased in BTLA-deficient mice independent of whether they
expressed CD27 and there was no change in the distribution of
gd T cell subsets (Figures S3D–S3I). Thus, although BTLA re-
stricts the expansion of all thymic gd T cells, this does not explain
the specific expansion of CD27 gd T cells in the periphery.
We further examined whether BTLA deficiency conferred a
competitive advantage to gd T cells undergoing homeostatic
expansionafter bonemarrow reconstitutionof irradiatedanimals.
We observed an increased proportion of BTLA-deficient gd
T cells among circulating lymphocytes at 3 or 8 weeks posttrans-
fer, demonstrating that BTLA-deficient progenitors outcompeted
their wild-type counterparts within these niches (Figures 3J–3L).
In addition,Btla/ gd T cell subsets outcompeted their wild-type
counterparts within the lymph nodes of reconstituted animals
(Figures 3M and 3N). However, within chimeras we observed
reduced numbers of Vg2+CD27 gd T cells from either donor,
which may reflect suboptimal development in the absence of
an embryonic environment (Haas et al., 2012).
In addition, the number of ILCs resident within gut-associated
lymphoid tissues did not differ between wild-type and BTLA-
deficient mice (Figure S3J). However, within mixed bone marrow
chimeric mice, we observed increased numbers of Btla/ ILCs
in the spleens of recipient mice (Btla/:Btla+/+ ratio of 1.8) (Fig-
ures S3K and S3L), indicating that BTLA deficiency provided a
competitive growth advantage compared to their wild-type
counterparts.
IL-7 and BTLA Form a Negative Feedback Loop
We reasoned that expansion of CD27 gd T cells in BTLA-defi-
cient mice in peripheral lymphoid organs may be due to unre-
stricted IL-7 receptor signaling because IL-7 is critical for gd
T cell homeostasis (Baccala et al., 2005) and preferentially
affects the CD27 subset (Michel et al., 2012). IL-7 treatment
sustained gd T cell viability in cultures of lymph node-derived
lymphocytes as compared to untreated cultures (Figure 4A).
Furthermore, BTLA-deficient gd T cells, and in particular
the CD27 subset, were hyperresponsive to IL-7 treatment
compared to wild-type controls, as measured by an increased
cell frequency and persistence in culture upon IL-7 stimulation
(Figures 4B–4F), which was not due to differences in the amount
of CD127 expression (Figure S4A). Thus, BTLA restricts gd T cell
responsiveness to IL-7.
We and others have shown activation-induced regulation of
BTLA expression in a cell-specific manner (Han et al., 2004; Hur-
chla et al., 2005). We assessed whether IL-7 stimulation itself
altered BTLA expression in gd T cells or ILCs by culturing iLN
and PP lymphocytes from Rorcgfp/+ mice in the presence of
IL-7 and analyzing BTLA expression 2 days later. Compared to
untreated controls, IL-7 induced a higher number of BTLA+ cells(J–N) Mice were lethally irradiated and reconstituted with a 1:1 mixture ofBtla+/+ (C
iLN at 8 weeks (M, N) after reconstitution were analyzed. Data are representative
medians; bar graphs show mean ± SEM of five mice.
(J) FACS plot indicates frequencies of gd T cell subsets in TCRgd+TCRb gated
(K and L) Percentage (%) of CD45.2+ Btla/ and CD45.2 Btla+/+ total gd T cells
(M andN) Frequencies of CD45.2+Btla/ andCD45.2Btla+/+CD27+ gd T cell sub
in iLN. Graphs show percentages of CD45.2+ Btla/ and CD45.2 Btla+/+ wit
(right bars).
See also Figure S3.
Immand increased surface BTLA expression in both gd T cells and
ILCs (Figures 4G–4K). Additionally, we found that BTLA expres-
sion in gd T cells was inducedwith IL-2 and that IL-7 upregulation
of BTLA depends upon signal transducer and activator of tran-
scription 5 (STAT-5) (Figures S4B and S4C). In contrast, IL-23
and IL-1b, two potent gd T cell activators (Sutton et al., 2009),
had either no or only a minimal effect in BTLA induction (Fig-
ure S4B). Thus, IL-7 signaling induces BTLA expression, which
in turn limits IL-7-dependent responses.
BTLA Inhibits gd T Cell Production of IL-17 and TNF
Mature gd T cells contribute to inflammatory responses through
the secretion of cytokines, IL-17, and TNF. We asked whether
BTLA inhibited the ability of gd T cells stimulated with IL-7
(Michel et al., 2012) to produce IL-17 and TNF. As expected,
among the gd T cell subsets a greater frequency of CD27 cells
expressed IL-17,whereasmoreCD27+ cells expressed TNF (Fig-
ure 5). IL-7 treatment enhanced the frequency of both IL-17- and
TNF-expressing cells in all subsets (Figure 5). However, more
CD27 gd T cells from BTLA-deficient mice produced IL-17 (Fig-
ures 5A and 5B) or TNF (Figures 5C and 5D) compared to CD27
wild-type cells, irrespective of exogenous IL-7. Moreover, there
was a higher frequency of IL-17-producing Btla/ gd T cells irre-
spective of Vg2 expression (Figure S5). Thus, BTLA negatively
regulates the homeostatic, preprogramed capacity of the
CD27 subset ofgd T cells to produce IL-17 and TNF. In contrast,
within the CD27+ subset of BTLA-deficient gd T cells, an overall
reduction in the frequency of TNF-expressing cells was observed
after IL-7 treatment (Figure 5). Together, these results indicate
that BTLA regulates cytokine production in gd T cell subsets in
a cell-specificmanner independent of its effects on homeostasis.
BTLA Inhibits gd T Cell-Dependent Dermatitis
gd T cells play critical roles in establishing skin inflammation
(Vantourout and Hayday, 2013). In mice, IL-17-producing gd
T cells have been shown to be the key initiators of imiquimod
(IMQ)-activated psoriasis (Pantelyushin et al., 2012), and we
reasoned that BTLA deficiency might confer susceptibility in
this model of disease. By using an acute dermatitis induction
model, we observed substantial inflammation in the skin of
BTLA-deficient animals compared to minimally affected wild-
type animals 3 days after a single dermal application of IMQ.
Within the skin of IMQ-treated Btla/ mice, there was exten-
sive erythema and more epidermal hyperplasia (Figures 6A,
6B, and S6A). In addition, the number of infiltrating gd
T cells that were CD27Vg3 (non-DETC) and expressed Vg2
(Figure S6B) concordantly increased in Btla/ animals, as did
the number of infiltrating Ly6G+ granulocytes (Figures 6C
and 6D). Btla/ mice showed increased skin gd T cells atD45.2) andBtla/ (CD45.2+) bonemarrow and with blood at 3 weeks (J–L) or
of five mice; in scatter graphs, each symbol represents a mouse and lines are
cells.
(K), or of CD45.2+ Btla/ and CD45.2 Btla+/+ gd T cell subsets (L) in blood.
sets (M) or of CD45.2+Btla/ andCD45.2Btla+/+CD27 gd T cell subsets (N)
hin CD27+ (M) or CD27 (N) subsets (left bars), and within Vg2+/ fractions
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Figure 4. IL-7 and BTLA Form a Negative Feedback Loop
Equal numbers of lymphocytes from the iLN of Btla+/+ and Btla/ mice were cultured for 4 days with or without 10 ng/ml IL-7.
(A) Expression of CD27 and Vg2 with or without IL-7 in TCRgd+TCRb gated cells.
(B) Percentage (%) of Btla+/+ and Btla/ CD27 gd T cells with or without IL-7.
(C–F) The fold difference in gd T cell cellularity as defined by the ratio of cell number with or without IL-7: (C) Vg2CD27 gd T cells, (D) Vg2+CD27 gd T cells, (E)
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(G–K) Lymphocytes from the iLN and PP of Rorcgfp/+ mice were enriched for ILCs and CD27 gd T cells and cultured with or without IL-7 for 2 days (cells are
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(G) Expression of BTLA and RORgt in iLN gd T cells (top) and PP ILCs (bottom) with or without IL-7.
(H) Numbers of BTLA+ iLN gd T cells.
(I) MFI for BTLA expression in iLN gd T cells.
(J) Numbers of BTLA+ PP ILCs.
(K) MFI for BTLA expression in PP ILCs.
FACS plots are representative of seven (iLN) or five (PP) independent experiments. In graphs each symbol represents an experiment and lines are medians.
See also Figure S4.
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BTLA Inhibits Inflammatory gd T Cellssteady state (Figures 6C and S6B), suggesting that the absence
of BTLA predisposes mice to skin inflammation. There was no
preferential expansion of CD27 gd T cells in lymph nodes
(Figure 6E), suggesting that the BTLA-dependent gd T cell1088 Immunity 39, 1082–1094, December 12, 2013 ª2013 Elsevier Inresponse was localized and occurred in the absence of a
systemic response. As previously shown, the response to
IMQ was independent of CD4+ ab T cells (Figures S6C–S6E;
Pantelyushin et al., 2012).c.
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Lymph node lymphocytes fromBtla+/+ andBtla/micewere cultured for 18 hr with or without IL-7 before stimulating with PMA and ionomycin for 3.5 hr and then
analyzed for cytokine production by flow cytometry.
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BTLA Inhibits Inflammatory gd T CellsUpon repeated application of IMQ (5 days), an overwhelming
inflammation occurred in both wild-type and Btla/ mice,
obscuring any significant differences in epidermal thickness or
infiltration of Ly6G-expressing granulocytes, although gd T cell
numbers remained increased in the skin of Btla/mice (Figures
S6H and S6I). In addition, we observed enlarged lymph nodes in
BTLA-deficient mice compared to wild-type mice and a higherImmfrequency of CD27 cells (Figures S6F and S6G), which consti-
tuted more than 80% of the gd T cell population in either genetic
background. This latter result indicates that the longer duration
of IMQ treatment resulted in a systemic response causing a
greater expansion of BTLA-deficient gd T cells.
In order to directly test whether BTLA could inhibit
dermatitis and inflammatory gd T cells, we used an agonisticunity 39, 1082–1094, December 12, 2013 ª2013 Elsevier Inc. 1089
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Figure 6. Btla–/– Animals Are Susceptible to
Dermatitis
Btla+/+ and Btla/ mice were treated once with
50 mg Aldara (IMQ) cream and were analyzed
3 days later (all data are representative of two
experiments).
(A) H&E staining of skin sections from untreated
or IMQ-treated Btla+/+ and Btla/ mice.
(B) Thickness of the epidermis in IMQ-treatedmice
(each symbol represents an epidermal region
within the tissue sections; data are pooled of three
mice per group).
(C–E) Percentage (%) of epidermal gd T cells
(TCRgd+Vg3) in untreated or IMQ-treated mice
(C), of epidermal Ly6G+ cells in IMQ-treatedBtla+/+
and Btla/ mice (D), and of lymph node (LN)
CD27 gdT cells in IMQ-treatedBtla+/+ andBtla/
mice (E). In (C) and (D), each symbol represents a
mouse and lines are medians. Mean ± SEM of four
mice shown in (E).
See also Figure S6.
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BTLA Inhibits Inflammatory gd T Cellsanti-BTLA antibody (clone 6A6) (Hurchla et al., 2005) in wild-
type animals treated with IMQ on days 1, 3, and 5 and
analyzed Vg2+CD27 gd T cell expansion and IL-17 produc-
tion within lymph nodes and skin. We found that BTLA
activation inhibited the IMQ-dependent increase of gd T cells
in lymph nodes and skin and reduced their capacity
to produce IL-17 (Figures 7A–7C). In parallel, we observed
significantly reduced epidermal thickening in animals
treated with anti-BTLA compared to control animals (Fig-
ures 7D and 7E). Thus, BTLA directly limits IMQ-induced
skin inflammation.1090 Immunity 39, 1082–1094, December 12, 2013 ª2013 Elsevier Inc.DISCUSSION
In the present study we demonstrate that
BTLA regulates the homeostasis of gd
T cells and ILCs in lymphoid tissues.
RORgt intrinsically suppresses BTLA
mRNA transcription, limiting BTLA trans-
lation and membrane expression,
whereas IL-7 increases BTLA membrane
expression to counterbalance RORgt.
Our observations define BTLA as a key
component in homeostasis that controls
the number of innate lymphocytes in sec-
ondary lymphoid tissues. BTLA also con-
trols IL-7-dependent proliferation and
production of IL-17 and TNF in mature
lymph node gd T cells. Thus, in response
to inflammatory stimuli, BTLA provides a
brake to autoimmune pathology that is re-
vealed in BTLA-deficient animals, which
contain a dysregulated proportion of in-
flammatory gd T cells, correlating with
increased susceptibility to dermatitis.
Our data link both theDNAandcofactor
binding domains of RORgt to its re-
pressive activity on Btla transcription.Although RORgt is not known to interact with corepressors, it
does interact with the coactivator Runx1 to drive IL-17 expres-
sion (Zhang et al., 2008). However, related ROR family members
RORa, RORb, and RORg, which regulate a variety of develop-
mental, circadian, and metabolic processes, are known to
interact with the corepressors NCOR1, NCOR2, RIP140, and
neuronal interacting factor in a ligand-independent fashion to
repress specific gene expression (Ho¨rlein et al., 1995; Jetten,
2009; Solt et al., 2011). Thus, it is not unreasonable to suggest
that RORgt may interact with corepressors, which act to limit
the expression of additional RORgt targets. Although it remains
AD E
B C
Figure 7. Treatment with Agonistic Anti-BTLA Inhibits gd T Cells and Restricts Dermatitis
Normal wild-type mice were treated three times with IMQ alone or with IMQ and anti-BTLA (6A6) antibody and at day 6 lymph nodes and skin were analyzed
(in graphs each symbol represents a mouse and line is median).
(A–C) Percentage (%) of lymph node Vg2+CD27 gd T cells in naive () and IMQ- or IMQ+6A6-treated animals (A), of lymph node Vg2+CD27IL-17+ gd T cells in
naive () and IMQ- or IMQ+6A6-treated animals (B), and of skin Vg2+CD27 gd T cells in naive () and IMQ- or IMQ+6A6-treated animals (C).
(D) H&E staining of skin sections from IMQ- or IMQ+6A6-treated animals
(E) Thickness of the epidermis in IMQ- or IMQ+6A6-treated animals (each symbol represents an epidermal region within the tissue sections; data are pooled of
four mice per group).
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BTLA Inhibits Inflammatory gd T Cellsunclear how specific promoter sequences are activated or
repressed by RORgt binding, this is probably a result of pro-
moter-specific cofactor recruitment. We therefore propose that
one of the mechanisms that regulate homeostasis of CD27 gd
T cells is via RORgt-dependent transcriptional downmodulation
of BTLA.
Our results showing that BTLA regulates IL-7-dependent
homeostasis of gd T cells and ILCs are consistent with previous
reports that BTLA regulates homeostasis of CD8+ memory
T cells and splenic dendritic cell subsets (De Trez et al., 2008;
Krieg et al., 2007). Although BTLA has not been reported to spe-
cifically regulate cytokine-induced signaling or cellular activation,
it was previously suggested that BTLA could regulate responses
to IL-2 or other cytokines (Krieg et al., 2007). The BTLA-binding
phosphatase SHP-1 has been found to inhibit signaling initiated
by IL-2 and IL-4 and probably binds directly to the cytokine re-
ceptors themselves to destabilize Janus kinase STAT signaling
complexes (Pao et al., 2007). It is unclear whether BTLA similarly
inhibits IL-7 receptor signaling, but a growing range of pathways
appears susceptible to BTLA-associated tyrosine phosphatase
activity including Toll-like receptor signaling (Kobayashi et al.,
2013). Together, these observations that IL-7 upregulates cell-
surface BTLA, which then limits IL-7 receptor signaling in gd
T cells, exemplifies a negative-feedback loop.
BTLA surface expression differs among polarized T helper
subsets, indicating that T cell expression of BTLA may be
determined by a combination of activating cytokines within the
differentiatingmilieu. For example, in Th1 cells BTLA is highly ex-Immpressed as compared to Th2 cells (Watanabe et al., 2003), indi-
cating that the GATA3, STAT, and T-box families of polarizing
transcription factors may be active in engaging their respective
binding sites within the conserved regions of the Btla promoter
(Loots et al., 2002). Consistent with RORgt-dependent regula-
tion of Btla transcription, we found that Th17 cells express sub-
stantially less (>2-fold) surface BTLA than do nonpolarized CD4+
T cells. In addition to TCR signals that drive the gd T cell fate
choice, CD27RORgt+ gd T cells probably develop in response
to IL-1 and IL-23 signaling (Sutton et al., 2009). It is unclear
why specific lymphocyte subsets show different responses to
BTLA activity, but one mechanism may involve subset-specific
intrinsic complexes between BTLA and HVEM or other cosignal-
ing molecules.
gd T cells have been implicated in a variety of inflammatory
diseases, supported by experimental evidence utilizing mouse
autoimmune models of psoriasis, multiple sclerosis, and dia-
betes (Vantourout and Hayday, 2013). Our findings using a gd
T cell-dependent model of inflammatory dermatitis contribute
to previous data that BTLA-deficient animals are prone to the in-
duction of autoimmune disease that in wild-type animals results
in subclinical outcomes (Watanabe et al., 2003). In addition,
BTLA control of early tissue-specific gd T cell-associated pathol-
ogy highlights the role of BTLA in regulation of innate-like cells.
These results find additional relevance in recent human
genome-wide association studies showing significant linkage
of HVEM to autoimmune diseases including multiple sclerosis
(Sawcer et al., 2011), celiac disease (Dubois et al., 2010),unity 39, 1082–1094, December 12, 2013 ª2013 Elsevier Inc. 1091
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BTLA Inhibits Inflammatory gd T Cellssclerosing cholangitis (Folseraas et al., 2012), and rheumatoid
arthritis (Coenen et al., 2009; Kurreeman et al., 2012).
The susceptibility of gd T cells to inhibitory signaling makes
BTLA an attractive target for selective biologics. In this regard,
a monoclonal antibody to BTLA (6A6) that competitively inhibits
the HVEM-BTLA interaction (Cheung et al., 2009) suppressed gd
T cell expansion and IL-17 production within lymph nodes and
skin after IMQ-induced inflammation.
Indeed, in several disease models, BTLA-specific antibodies
can alter disease progression (Murphy and Murphy, 2010). We
determined that BTLA is also required for optimal inflammatory
cytokine production from the CD27+ gd T cell subset, potentially
serving to integrate signals that sustain survival during effector
and memory cell differentiation as occurs in conventional ab
T cells (Steinberg et al., 2008) and perhaps in conjunction with
CD27 or other costimulatory TNF receptor members. These
data suggest that selective activation of BTLA may restore the
balance of these preprogrammed gd T cell subsets and/or
the repertoire of gd T cell specificity in order to control autoim-
mune pathogenesis. Collectively, we demonstrate a molecular
pathway in which RORgt and IL-7 coordinate the expression
of BTLA and thus balance suppressive and activation stimuli
to regulate the homeostasis and inflammatory responses of
gd T cells.
EXPERIMENTAL PROCEDURES
Mice and Mouse Cell Preparations
All experiments were approved by the SanfordjBurnham IACUC. Mice were
bred in a C57BL/6 background and housed in the SBMRI animal facility.
Rorcgfp/+, Btla/, and B6.SJL-PtprcaPep3/BoyJ mice were from Jackson.
Rag2/Il2rg/mice were from Taconic. Transfer of BM cells (23 106/mouse)
was performed by retro-orbital injection. iLN, PP, or spleen cells were passed
through a 70 mm strainer. ILCs and CD27 gdT cells were enriched with the BD
IMag system (BD Biosciences). BM cells were flushed from femurs with PBS.
Small intestinal lamina propria lymphocytes were prepared as previously
described (Steinberg et al., 2008).
Flow Cytometry
Surface staining was performed on ice for 20–30 min. Intracellular staining
was performed with the BD Cytofix/Cytoperm Kit according to the manufac-
turer’s instructions (BD Biosciences). Antibodies and data acquisition are
described in the Supplemental Experimental Procedures.
Imiquimod Treatment and Histology
A total of 50 mg of commercially available Aldara (5% imiquimod) cream
was applied on the shaved backs of mice once or three times every other
day. Three days later, animals were sacrificed and epidermal lymphocytes
were prepared by incubating the tissue in 0.25% Trypsin-EDTA solution
for 2 hr. Alternatively, mice were treated daily for 5 consecutive days before
analysis. Anti-BTLA (6A6 clone, BioXCell) injections were performed i.p. with
100 mg antibody per mouse 1 day before IMQ and then a day after each IMQ
application. Formalin-fixed tissue was embedded in paraffin and H&E-
stained sections were scanned with ScanScope XT system at 203.
Promoter Analysis
The human and mouse promoter regions were aligned with VISTA (http://
genome.lbl.gov/vista) using a region 15 kb upstream and 1 kb downstream
of the transcription start of each gene, with the additional identification of
the common RORa-RORgt binding site (Jetten, 2009). Chromatin immunopre-
cipitationwas performed from the RORgt-transfected PE16 T cell line with 2 mg
aRORg (Santa Cruz Biotechnology) or 2 mg control rabbit Ig with the Simple-
Chip Kit (Cell Signaling Technology).1092 Immunity 39, 1082–1094, December 12, 2013 ª2013 Elsevier InIn Vitro Cultures
For IL-7-induced expansion, iLN lymphocytes were cultured in RF10 media
(RPMI+10% FBS,p/s,L-Glutamine) at 107/ml in 12-well plates for 4 days.
For IL-7-induced BTLA expression, iLN or PP lymphocytes were enriched
for ILCs and CD27 gd T cells and cultured in RF10 media in 24-well plates
containing feeder adherent cells for 2 days. After enrichment, cells from three
animals were cultured in 1 ml in a single well. IL-7 (R&D Systems) was added
at 10 ng/ml. For IL-17 and TNF production, whole lymph node cells were
cultured with or without 10 ng/ml IL-7 for 18 hr and then restimulated with
PMA (50 ng/ml), ionomycin (750 ng/ml), and Golgi Stop (BD Biosciences)
for 3.5 hr. Th17 cell differentiation was performed by isolating CD4+ T cells
from spleens and culturing in anti-CD3 (5 mg/ml)-coated 24-well plates at
1.35 3 106/ml with anti-CD28 (2 mg/ml), IL-6 (20 ng/ml), and TGF-b1
(2 ng/ml). At day 5, cells were washed and restimulated with PMA+ionomycin
and Golgi Stop (BD Biosciences) for 3.5 hr. For induction of human IL-22,
tonsil lymphocytes were cultured in RF10 media at 1.5 3 106/ml in 24-well
plates for 6 hr in the presence of 40 ng/ml IL-23 (eBiosciences) and
10 ng/ml IL-1b (R&D Systems). Golgi Stop (BD Biosciences) was added
during the final 3 hr.
Statistical Analysis and Software
All FACS data were acquired and compensated with BD FACSDiva v.6.2 soft-
ware and analyzed with FlowJo v.9.5.2. Graphs were plotted with Prism 6.0c.
Statistical analysis via 2-way ANOVA in R software was used to correct for var-
iations in the mean fluorescent intensities (MFI) between FACS experiments
and uses the following formula: lm.X = lm(Responsey1+y2, data = A), where
X = a given set of data, Response = the MFI, y1 = variable 1 as defined in a
given FACS experiment with specific cytometer settings, and y2 = variable 2
defined as the two nonnumerical treatment groups to be compared (e.g.,
gdT versus abT cells). All other statistical analyses (comparisons of cell
numbers or cell expansion) were performed with the Mann-Whitney U-test
or t test in Prism.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.immuni.2013.10.017.
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